☆ 4.6 Article

The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section

JOURNAL OF INFECTION AND PUBLIC HEALTH (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A. Ivashchenko et al.

Summary: In May 2020, AVIFAVIR, an RNA polymerase inhibitor, was granted fast-track marketing authorization by the Russian Ministry of Health for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR demonstrated a 62.5% viral clearance rate within 4 days for SARS-CoV-2 patients and was shown to be safe and well-tolerated.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size

Hong Zhao et al.

Summary: The study found that tocilizumab combined with or without favipiravir can effectively improve pulmonary inflammation in COVID-19 patients, alleviate clinical symptoms, and help blood routine return to normal.

BIOMEDICINE & PHARMACOTHERAPY (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

Yan Lou et al.

Summary: Effective antiviral drugs for COVID-19 are still lacking and this study aimed to evaluate the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in COVID-19 patients. In vitro evaluation showed that baloxavir acid exhibited antiviral activity, while favipiravir did not demonstrate significant antiviral activity. However, the addition of either baloxavir marboxil or favipiravir under the trial dosages did not show clear benefits compared to standard treatment.

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2021)

添加到收藏夹

Article Allergy

Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19

Jonathan T. Sims et al.

Summary: This study investigated circulating biomarkers in COVID-19 patients compared to healthy controls, revealing a hyperinflammatory environment and markers of vascular endothelial damage in patients. As the disease progresses, there is significant dysregulation of immune response proteins.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial

Olivier Hermine et al.

Summary: In this clinical trial of COVID-19 patients with pneumonia requiring oxygen support but not in the ICU, tocilizumab did not reduce WHO-CPS scores below 5 by day 4 but may have reduced the risk of needing noninvasive ventilation, mechanical ventilation, or death by day 14. There was no difference in mortality by day 28. Further studies are needed to confirm these preliminary results.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia A Randomized Clinical Trial

Carlo Salvarani et al.

Summary: This study evaluated the use of tocilizumab in hospitalized COVID-19 pneumonia patients and found no significant benefit compared to standard care. Further randomized clinical trials with blinded, placebo-controlled methods are needed to confirm these results and explore potential applications of tocilizumab in different stages of the disease.

JAMA INTERNAL MEDICINE (2021)

添加到收藏夹

Article Virology

被撤回的出版物: Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study (Retracted article. See vol. 167, pg. 277, 2022)

Hany M. Dabbous et al.

Summary: Favipiravir shows promising efficacy in the treatment of COVID-19, reducing hospital stay and the need for mechanical ventilation.

ARCHIVES OF VIROLOGY (2021)

添加到收藏夹

Article Immunology

Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial

Payam Tabarsi et al.

Summary: The study aimed to investigate the potential usefulness of IVIg in treating severe COVID-19 cases. The results did not support the use of IVIg in combination with other drugs in significantly reducing mortality rate and medical interventions.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

Faryal Khamis et al.

Summary: The study evaluated the therapeutic effectiveness of favipiravir combined with inhaled interferon beta 1b compared to hydroxychloroquine in adult patients hospitalized with moderate to severe COVID-19 pneumonia. The results showed no significant differences in inflammatory markers, length of hospital stay, discharges, or overall mortality between the two treatment groups. In conclusion, there were no differences in clinical outcomes between favipiravir plus inhaled interferon beta 1b and hydroxychloroquine in this patient population.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial

Viviane C. Veiga et al.

Summary: The study found that in patients with severe or critical COVID-19, tocilizumab in combination with standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Critical Care Medicine

Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update

Waleed Alhazzani et al.

Summary: The Surviving Sepsis Campaign Coronavirus Disease 2019 panel issued nine statements on managing severe or critical coronavirus disease 2019 in the ICU, including recommendations for systemic corticosteroids and venous thromboprophylaxis while strongly advising against the use of hydroxychloroquine. The panel also made suggestions for the use of dexamethasone, remdesivir, convalescent plasma, and therapeutic anticoagulation, based on the available evidence.

CRITICAL CARE MEDICINE (2021)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial

Zarir F. Udwadia et al.

Summary: The study aimed to assess the efficacy and safety of favipiravir in adults with mild-to-moderate COVID-19. Results showed a significant improvement in time to clinical cure with favipiravir, although there was no statistically significant difference in viral shedding cessation time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Medicine, General & Internal

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysis

Perrine Janiaud et al.

Summary: Convalescent plasma treatment showed no significant decrease in all-cause mortality or benefit for other clinical outcomes compared to placebo or standard of care. The certainty of the evidence ranged from low to moderate for all-cause mortality and remained low for other outcomes.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Immunology

A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy

R. S. Raman et al.

Summary: The study demonstrates that intravenous immunoglobulin (IVIG) is safe and effective in the treatment of COVID-19 patients, reducing hospital stay and promoting recovery. IVIG can be used as an adjunct therapy with other antiviral drugs in clinical practice.

JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

I. O. Rosas et al.

Summary: In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19

Anthony C. Gordon et al.

Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open- label, multicentre, randomised, controlled, phase 3 trial

Arvinder S. Soin et al.

Summary: The study recruited 180 patients and found that tocilizumab did not reduce disease progression in patients with moderate to severe COVID-19, but may have some effect in severe cases.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections

S. Saqrane et al.

Summary: Remdesivir, an emerging potential therapeutic option for COVID-19, interferes with the virus replication cycle and has shown activity against MERS-CoV and SARS-CoV coronaviruses. It is currently being evaluated in numerous clinical trials and recommendations for its use against COVID-19 infection are summarized in this work.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2021)

添加到收藏夹

Article Hematology

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Adam Cuker et al.

Summary: The American Society of Hematology provided two conditional recommendations for anticoagulation in COVID-19-related critical illness and acute illness, emphasizing the low certainty in the evidence and the importance of future high-quality randomized controlled trials for validation.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Infectious Diseases

Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study

Khalid A. Al Sulaiman et al.

Summary: This study extensively described the clinical features and outcomes in critically ill patients with COVID-19 in Saudi Arabia, identifying several variables associated with an increased risk of ICU mortality at 30 days. Respiratory failure requiring MV, AKI, and thrombosis were the most common complications during ICU stay.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani et al.

LANCET (2021)

添加到收藏夹

Review Multidisciplinary Sciences

The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Soheil Hassanipour et al.

Summary: The meta-analysis of Favipiravir in the treatment of COVID-19 showed significant clinical improvement in the Favipiravir group compared to the control group after seven days of hospitalization. However, there was no significant difference in viral clearance and oxygen therapy requirement between the two groups. The mortality rate was approximately 30% lower in the Favipiravir group, but this finding was not statistically significant.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Editorial Material Infectious Diseases

COVID-19: combining antiviral and anti-inflammatory treatments

Justin Stebbing et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Immunology

Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019

Xiaohua Chen et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Letter Infectious Diseases

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Fabrizio Cantini et al.

JOURNAL OF INFECTION (2020)

添加到收藏夹

Article Microbiology

Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2

Rudramani Pokhrel et al.

JOURNAL OF MEDICAL MICROBIOLOGY (2020)

添加到收藏夹

Letter Medicine, General & Internal

COVID-19: consider cytokine storm syndromes and immunosuppression

Puja Mehta et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Association Between Oral Corticosteroid Bursts and Severe Adverse Events A Nationwide Population-Based Cohort Study

Tsung-Chieh Yao et al.

ANNALS OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Hematology

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Hanny Al-Samkari et al.

BLOOD (2020)

添加到收藏夹

Letter Medicine, General & Internal

Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System

Seda Bilaloglu et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial

Ling Li et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Review Medicine, General & Internal

Venous Thromboembolism among Hospitalized Patients with COVID-19 Undergoing Thromboprophylaxis: A Systematic Review and Meta-Analysis

Gerald Chi et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Review Public, Environmental & Occupational Health

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses

E. Susan Amirian et al.

ONE HEALTH (2020)

添加到收藏夹

Article Infectious Diseases

The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial

Naser Gharebaghi et al.

BMC INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Public, Environmental & Occupational Health

Hydroxychloroquine safety: A meta-analysis of randomized controlled trials

Khalid Eljaaly et al.

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)

添加到收藏夹

Editorial Material Critical Care Medicine

The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19

Yaseen M. Arabi et al.

INTENSIVE CARE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 A Meta-analysis

Jonathan A. C. Sterne et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Peter Horby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

John H. Stone et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Virology

Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis

Dhan Bahadur Shrestha et al.

VIROLOGY JOURNAL (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

A living WHO guideline on drugs for covid-19

Francois Lamontagne et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Systematic review and meta-analysis of effectiveness and safety of favipiravir in the management of novel coronavirus (COVID-19) patients

Ajay Prakash et al.

INDIAN JOURNAL OF PHARMACOLOGY (2020)

添加到收藏夹

Review Pharmacology & Pharmacy

Evaluation of the Effect of Intravenous Immunoglobulin Dosing on Mortality in Patients with Sepsis: A Network Meta-analysis

Yi Yang et al.

CLINICAL THERAPEUTICS (2019)

添加到收藏夹

Article Oncology

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Robert Q. Le et al.

ONCOLOGIST (2018)

添加到收藏夹

Article Rheumatology

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes

Mark C. Genovese et al.

RHEUMATOLOGY (2018)

添加到收藏夹

Review Critical Care Medicine

Conflicts of interest disclosure forms and management in critical care clinical practice guidelines

Waleed Alhazzani et al.

INTENSIVE CARE MEDICINE (2018)

添加到收藏夹

Article Rheumatology

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

Hermine I. Brunner et al.

ANNALS OF THE RHEUMATIC DISEASES (2015)

添加到收藏夹

Review Pharmacology & Pharmacy

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

Yousuke Furuta et al.

ANTIVIRAL RESEARCH (2013)

添加到收藏夹

Article Critical Care Medicine

Hyperimmune IV Immunoglobulin Treatment A Multicenter Double-Blind Randomized Controlled Trial for Patients With Severe 2009 Influenza A(H1N1) Infection

Ivan F. N. Hung et al.

CHEST (2013)

添加到收藏夹

Article Health Care Sciences & Services

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations

Jeff Andrews et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)

添加到收藏夹

Article Health Care Sciences & Services

GRADE guidelines: 12. Preparing Summary of Findings tables-binary outcomes

Gordon H. Guyatt et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2013)

添加到收藏夹

Article Health Care Sciences & Services

GRADE guidelines: 3. Rating the quality of evidence

Howard Balshem et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)

添加到收藏夹

Review Rheumatology

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

Laura Campbell et al.

RHEUMATOLOGY (2011)

添加到收藏夹

Article Microbiology

Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice

Donald F. Smee et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

添加到收藏夹

Article Microbiology

In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses

Katrina Sleeman et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

Shumpei Yokota et al.

LANCET (2008)

添加到收藏夹

Editorial Material Medicine, General & Internal

GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations

Gordon H. Guyatt et al.

BRITISH MEDICAL JOURNAL (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.